Antibody biodistribution coefficients
暂无分享,去创建一个
[1] J. Balthasar,et al. Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts , 2012, The AAPS Journal.
[2] Dhaval K. Shah,et al. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[3] Christilyn P. Graff,et al. Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration , 2011, Journal of Pharmacology and Experimental Therapeutics.
[4] W. Oyen,et al. Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 , 2011, Clinical Cancer Research.
[5] F. Theil,et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. , 2011, Bioconjugate chemistry.
[6] W. Oyen,et al. Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody , 2011, The Journal of Nuclear Medicine.
[7] Y. Vugmeyster,et al. Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice , 2010, mAbs.
[8] Jos H. Beijnen,et al. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[9] Y. Vugmeyster,et al. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. , 2010, Journal of pharmaceutical sciences.
[10] A. Scott,et al. Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers , 2009, Clinical Cancer Research.
[11] D. Benjamin,et al. The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity , 2009, Journal of Pharmacology and Experimental Therapeutics.
[12] Joseph P. Balthasar,et al. Investigation of the Influence of FcRn on the Distribution of IgG to the Brain , 2009, The AAPS Journal.
[13] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[14] Y. Vugmeyster,et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. , 2008, International immunopharmacology.
[15] Joseph P. Balthasar,et al. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[16] R. Senekowitsch,et al. Pharmacokinetics of reshaped MAb 425 in three animal species , 1995, Cell Biophysics.
[17] A. Garg. Investigation of the role of FcRn in the absorption, distribution, and elimination of monoclonal antibodies , 2007 .
[18] C. R. Leemans,et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] B. Cornelissen,et al. In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model , 2005, Clinical Cancer Research.
[20] José de Souza Filho,et al. Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131 , 2005 .
[21] Anna M. Wu,et al. A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.
[22] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[23] D. Bigner,et al. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. , 2004, Nuclear medicine and biology.
[24] W. Oyen,et al. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. , 2004, Cancer biotherapy & radiopharmaceuticals.
[25] Hongsheng Xie,et al. Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.
[26] Ryosei Kawai,et al. Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[27] L. Khawli,et al. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. , 2002, Cancer biotherapy & radiopharmaceuticals.
[28] V. Muzykantov,et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[29] W. Pardridge,et al. Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier , 2001, Journal of Neuroimmunology.
[30] L. Zuckier,et al. Expression of human tumor mucin-associated carbohydrate epitopes, including sialylated Tn, and localization of murine monoclonal antibodies CC49 and B72.3 in a syngeneic rat colon carcinoma model. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[31] R K Jain,et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.
[32] J. Baak,et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. , 1993, Cancer research.
[33] F. Buchegger,et al. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] V. Muzykantov,et al. Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] J. Eary,et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. , 1991, Blood.